The company specializes in developing neuroprotective/neurorestorative therapies for early-stage Parkinson's disease, levodopa-enhancing and anti-dyskinesia therapy for mid-stage patients, and gene therapies for advanced patients. Lazarus Therapeutics was incorporated in 2006 and is based in West Chester, Pennsylvania.